As previously reported, Maxim Jason McCarthy upgraded Theriva Biologics (TOVX) to Buy from Hold with a $1 price target The firm says the the path forward for VCN-01 in first-line metastatic pancreatic cancer becomes clearer and more capital-efficient, the analyst tells investors in a research note. If Theriva can “dial in” the dosing of VCN-01 to maximize improvements in overall survival, that could be de-risking for a Phase 3 program and for potential partnering for that program, Maxim added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics upgraded to Buy from Hold at Maxim
- Theriva Biologics Advances VCN-01 Into Pivotal Phase 3
- Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA
- Theriva Biologics price target lowered to $4 from $7 at Alliance Global
- Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year